Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ET

Company Participants

Stephanie Diaz - Investor Relations

Brian Lian - President and Chief Executive Officer

Gregory Zante - Chief Financial Officer

Conference Call Participants

Joon So Lee - Truist Securities

Steven Seedhouse - Raymond James & Associates

Joseph Pantginis - H.C. Wainwright

Andy Hsieh - William Blair

Yale Jen - Laidlaw & Company

Scott Henry - ROTH MKM Partners

Justin Zelin - BTIG

Nazibur Rahman - Maxim Group

Operator

Welcome to the Viking Therapeutics Fourth Quarter and Full-year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question and answer session. [Operator Instructions] As a reminder, this conference call is being recorded today, February 8, 2023.

I would now like to turn the over to Viking’s Manager of Investor Relations, Stephanie Diaz. Please go ahead.

Stephanie Diaz

Hello and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; and Greg Zante, Viking’s CFO.

Before we begin, I would like to caution that comments made during this conference call today, February 8, 2023, will contain Forward-Looking Statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, time lines and milestones.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today’s date, and the Company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the Company’s filings with the Securities and Exchange Commission concerning these and other matters.

I will now turn the call over to Brian Lian for his initial comments.

Brian Lian

Thanks, Stephanie, and good afternoon to everyone dialed in by phone or listening on the webcast. Today, we will review our financial results for the fourth quarter and full-year 2022 and provide an update on recent progress with our clinical programs and operations.

2022 was an exciting year for Viking as we expanded our development pipeline and advanced each of our three clinical programs. With respect to VK2809, our lead drug candidate for the treatment of NASH and fibrosis, we recently announced completion of enrollment in our Phase IIb VOYAGE trial, and we expect to announce top line data from this study in the second quarter of 2023.